Biosimilars and Interchangeable Biologics: Strategic Elements

Sarfaraz K. Niazi

September 30, 2017 by CRC Press
Reference - 599 Pages - 13 Color & 16 B/W Illustrations
ISBN 9781138775503 - CAT# K32783

USD$94.95

Add to Wish List
FREE Standard Shipping!

Features

    • Examines the regulatory, marketing, and intellectual property challenges to carve out a stable marketing strategy
    • Features an understanding of global regulations in developing a comprehensive plan
    • Incorporates the author’s firsthand experience in developing biosimilar drugs for both the US and European markets

    Summary

    What’s the Deal with Biosimilars?

    Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biological drugs are produced by recombinant DNA technology that allows for large-scale production and an overall reduction time in costs and development.

    Part of a two-volume set that covers varying aspects of biosimilars, Biosimilars and Interchangeable Biologics: Strategic Elements explores the strategic planning side of biosimilar drugs and targets issues surrounding biosimilars that are linked to legal matters. This includes principal patents and intellectual property, regulatory pathways, and concerns about affordability on a global scale. It addresses the complexity of biosimilar products, and it discusses the utilization of biosimilars and related biological drugs in expanding world markets.

    Of specific interest to practitioners, researchers, and scientists in the biopharmaceutical industry, this volume examines the science, technology, finance, legality, ethics, and politics of biosimilar drugs. It considers strategic planning elements that include an overall understanding of the history and the current status of the art and science of biosimilars, and it provides detailed descriptions of the legal, regulatory, and commercial characteristics. The book also presents a global strategy on how to build, take to market, and manage the next generation of biosimilars throughout their life cycle.

    Share this Title